Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up

• Published in: The International Journal of Cardiovascular Imaging 2018-03, Vol.34 (3), p.353-365
• Main Authors: Gil, Robert J., Bil, Jacek, Legutko, Jacek, Pawłowski, Tomasz, Gil, Katarzyna E., Dudek, Dariusz, Costa, Ricardo A.
• Format: Article
• Language: English
• Subjects: Angiography; Biodegradability; Biodegradable materials; Biodegradation; Cardiac Imaging; Cardiology; Chromium; Cobalt; Data processing; Drug delivery; Imaging; Implants; Medical imaging; Medicine; Medicine & Public Health; Optical Coherence Tomography; Original Paper; Patients; Platforms; Polymers; Radiology; Rapamycin; Stainless steel; Statistical analysis; Stents; Struts; Subgroups; Surgical implants; Tomography
• ISSN: 1569-5794; 1573-0743; 1875-8312
• DOI: 10.1007/s10554-017-1251-7

The aim of this study was to compare neointima proliferation in three drug-eluting stents (DES) produced by the same company (Balton, Poland) which are covered with a biodegradable polymer and elute sirolimus (concentration: 1.0 and 1.2 µg/mm 2 ), but have different stent platforms and strut thickness: stainless steel Prolim ® (115 µm) and BiOSS LIM ® (120 µm) and cobalt-chromium Alex ® (70 µm). We analyzed data of patients with quantitative coronary angiography (QCA) and optical coherence tomography (OCT) at 12 months from BiOSS LIM Registry, Prolim Registry and Alex OCT clinical trial. There were 56 patients enrolled, in whom 29 Prolim ® stents were deployed, in 11—BiOSS LIM ® and in 16—Alex stents. The late lumen loss was the smallest in Prolim ® subgroup (0.26 ± 0.17 mm) and did not differ from Alex ® subgroup (0.28 ± 0.47 mm). This parameter was significantly bigger in BiOSS ® subgroup (0.38 ± 0.19 mm; p